Alembic Pharmaceuticals Limited has informed the Exchange about Transcript
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals reported Q1 FY'26 revenue of Rs. 1,711 crores, up 10% year-on-year, driven by broad-based growth despite US pricing pressure. Gross margin improved to 76.2% from 74.8%, helped by better product mix and manufacturing cost programs. EBITDA before R&D grew 23% to Rs. 424 crores (25% margin), while net profit rose 15% to Rs. 154 crores. The India branded business underperformed with only 5% growth to Rs. 599 crores due to execution issues and tighter UCPMP-aligned sales practices. The US business grew 13% with 4 new launches, and Rest of World generics surged 21%, while API was flat at Rs. 261 crores due to pricing erosion from industry-wide data leakage. Management guided for US growth of 10-15% and RoW growth of 10-15% for the full year, and expects India to return to double-digit growth within months.
The Q1 performance was mixed — strong international growth and margin expansion are positives, but the weak India business and flat API segment are near-term concerns. Investors should watch India execution recovery and US launch traction in upcoming quarters as key catalysts, while the new CFO's cautious approach to debt reduction signals no major deleveraging push this year.